# Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3

> **NCT02322788** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 95 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Terbutaline sulphate
- **DRUG:** Terbutaline sulphate
- **DRUG:** Placebo for terbutaline sulphate
- **DRUG:** Placebo for terbutaline sulphate

## Key facts

- **NCT ID:** NCT02322788
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2017-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02322788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02322788, "Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02322788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*